Quality of life of patients with asthma on beclomethasone/formoterol. Cost-utility analysis

• Published in: Semergen, medicina de familia Vol. 42; no. 4; pp. 225 - 234
• Main Authors: García-Ruiz, A J, Quintano Jiménez, J A, García-Agua Soler, N, Ginel Mendoza, L, Hidalgo Requena, A, Del Moral, F
• Format: Journal Article
• Language: Spanish
• Published: Spain 01.05.2016
• Subjects: Adult; Aged; Anti-Asthmatic Agents - administration & dosage; Anti-Asthmatic Agents - economics; Asthma - drug therapy; Asthma - economics; Beclomethasone - administration & dosage; Beclomethasone - economics; Cost-Benefit Analysis; Drug Combinations; Female; Formoterol Fumarate - administration & dosage; Formoterol Fumarate - economics; Humans; Male; Middle Aged; Primary Health Care; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Beclomethasone; Análisis coste-utilidad; Pharmacoeconomics; Asma; Formoterol; Cost-utility analysis; Beclometasona; Calidad de vida; Farmacoeconomía; Asthma; Quality of life
• ISSN: 1578-8865
• DOI: 10.1016/j.semerg.2015.05.004

To perform a cost-utility analysis on asthmatic patients on beclomethasone/formoterol fixed combination in Primary Health Care. Material and methods Non-probability sampling was used to select a group of asthmatic patients with moderate/severe persistent severity (GEMA 2009), treated with beclomethasone/formoterol fixed combination, over 18 years, had given their informed consent. The study observation period was 6 months. The variables studied were: age, sex, duration of disease, health resources used, analysis of health related quality of life by EQ-5D and SF-36, and the specific Asthma Quality of Life Questionnaire. For the qualitative variables, the frequency and percentages were calculated, and for the quantitative variables, the mean, SD and 95% CI. Chi-square, Student t-test and ANOVA were used for statistical inference. Comparisons were made with a statistical significance of 0.05. Of the 64 patients that completed the study, 59.4% were female. The mean age was 49 years, and mean disease duration was 93 months. For asthma control, 53% of patients had a prescription pattern of one/12h. All health related quality of life scales were modified with respect to the baseline and the differences were statistically significant. Our patients had a better health related quality of life than Spanish asthma cohort. The incremental cost utility beclomethasone/formoterol versus usual treatment option was € 6,256/QALY.